Facilitating Access to Treatment for Children with Brain Cancer
Please find the full article here.
-
Our Team
Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.Learn more -
Our Science
Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.Learn more -
Alliances
MD Anderson Cancer Center and Massachusetts General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.Learn more
In The News
-
MAR 26 2020
-
-
JAN 29 2020
OncologyTube: Dr. Arrillaga talks about her experience with ONC201 in patients with glioma
Isabel Arrillaga-Romany, MD, PhD @MGHNeuroOnc @Oncoceutics explains how this is going to affect clinicians today and what clinicians should know about patients with the H3 K27 mutation. Content Warning: These Videos Are Intended for Doctors and Health Care Professionals. What should clinicians know about patients with the H3 K27M mutation? ONC201 in adult recurrent GBM
-
Press Releases
Events
Business Development
© Copyright 2016 Oncoceutics, Inc. All Rights Reserved.